Quick Answer
iSpecimen Inc. reported Net Income Loss of -$12.50 million for the year ending 2024.
- iSpecimen Inc. showed a decrease of -12.6% in Net Income Loss from 2023 to 2024.
- This data is from iSpecimen Inc.'s annual report (Form 10-K), filed with the SEC on April 14, 2025.
- XBRL data for this metric is available from 2020 to 2024 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$1.64 million | Q2 2020: -$174.1 thousand | Q3 2020: -$1.25 million | Q1 2021: -$3.96 million | Q2 2021: -$1.39 million | Q3 2021: -$1.55 million | Q1 2022: -$2.38 million | Q2 2022: -$2.61 million | Q3 2022: -$3.10 million | Q1 2023: -$2.43 million | Q2 2023: -$3.48 million | Q3 2023: -$2.11 million | Q1 2024: -$2.90 million | Q2 2024: -$2.11 million | Q3 2024: -$1.44 million | Q1 2025: -$1.66 million | Q2 2025: -$1.05 million | Q3 2025: -$2.78 million.
- Over the full 5 years of available data (2020 to 2024), iSpecimen Inc.'s Net Income Loss has declined by 168.6%.
- Historical annual values: Fiscal year 2024: -$12.50 million | Fiscal year 2023: -$11.10 million | Fiscal year 2022: -$10.25 million | Fiscal year 2021: -$8.96 million | Fiscal year 2020: -$4.65 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: